Skip to main content
. 2014 Feb 25;111(9):1693–1702. doi: 10.1038/bjc.2014.86

Figure 4.

Figure 4

Solid trend line (blue): England 3 monthly moving average. Dashed trend line (red): Wales 3 monthly moving average. Thick line-Cancer Drugs Fund established (October 2010). Solid line-NICE recommended decision. Dashed line-NICE not recommended decision. No NICE appraisal pre-CDF (lapatinib, panitumumab). (A) Lapatinib. (B) Panitumumab. The color reproduction of this figure is available on the BJC journal online.